# Phase Ⅱ Study of Adductor Canal Block With HR18034 for Postsurgical Pain Management

> **NCT05561309** · PHASE2 · UNKNOWN · sponsor: **Shanghai Hengrui Pharmaceutical Co., Ltd.** · enrollment: 89 (actual)

## Conditions studied

- Total Knee Arthroplasty

## Interventions

- **DRUG:** HR18034;Ropivacaine Hydrochloride Injection

## Key facts

- **NCT ID:** NCT05561309
- **Lead sponsor:** Shanghai Hengrui Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-10-20
- **Primary completion:** 2024-12
- **Final completion:** 2024-12
- **Target enrollment:** 89 (ACTUAL)
- **Last updated:** 2024-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05561309

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05561309, "Phase Ⅱ Study of Adductor Canal Block With HR18034 for Postsurgical Pain Management". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05561309. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*